Skip to content
  • Investors
  • News & Events
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join Our Team
  • Investors
  • News
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join The Team
  • Investors
  • News
  • Contact Us
Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Stock Quote
    • Charting
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

Jan 23, 2019 7:30am EST

Rigel Pharmaceuticals Provides Business Update

Jan 07, 2019 7:30am EST

Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

Jan 03, 2019 4:30pm EST

Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City

Dec 05, 2018 7:30am EST

Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

Nov 06, 2018 4:01pm EST

Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition

Nov 01, 2018 4:01pm EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results

Oct 30, 2018 7:30am EDT

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSEā„¢ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

Oct 29, 2018 8:00am EDT

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Oct 11, 2018 7:30am EDT

Rigel to Host Investor & Analyst Day in New York City on October 4, 2018

Sep 27, 2018 7:30am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...31
    Next
    • Email Alerts
    • Tear Sheet
    • RSS News Feed
    • Terms of Use
    • Privacy Policy

    © 2021 Rigel Pharmaceuticals, Inc. All rights reserved.
    TAVALISSE and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.
    TAVA_ITP-19277

    • facebook
    • twitter
    • linkedin
    © 2021 Rigel Pharmaceuticals • Powered by GeneratePress